

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 5, 2015**

**AngioDynamics, Inc.**  
(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction of Incorporation)

**000-50761**  
(Commission File  
Number)

**11-3146460**  
(IRS Employer  
Identification No.)

**14 Plaza Drive Latham, New York**                      **12110**  
(Address of Principal Executive Offices)                      (Zip Code)

**(518) 795-1400**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
-

**Item 7.01 – Regulation FD Disclosure.**

On August 5, 2015, Mark Frost, Executive Vice President and Chief Financial Officer of AngioDynamics, Inc. (the "Company"), will make a presentation to certain investors at the UBS 2015 SMID Cap One-on-One Conference. The conference slides are furnished herewith as Exhibit 99.1.

The slides are being furnished pursuant to Item 7.01 and the information contained therein shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information in Exhibit 99.1 shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

**Item 9.01 – Financial Statements and Exhibits.**

(d) *Exhibits.*

<u>Exhibit No.</u>	<u>Description</u>
99.1	Presentation slides for the UBS 2015 SMID Cap One-on-One Conference on August 5, 2015.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.  
(Registrant)

Date: August 5, 2015

By: /s/ Stephen A. Trowbridge  
Stephen A. Trowbridge  
Senior Vice President and General Counsel

---

**EXHIBIT INDEX**

Exhibit No.

Description

99.1

Presentation slides for the UBS 2015 SMID Cap One-on-One Conference on August 5, 2015.

---

# UBS 2015 SMID Cap One-on-One Conference

Mark Frost, Executive Vice President & CFO  
August 5, 2015



# Forward-Looking Statements

## Notice Regarding Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2014; its Annual Report on Form 10-K/A for the fiscal year ended May 31, 2014; its quarterly reports on form 10-Q for the fiscal quarters ended August 31, 2014, and November 30, 2014; and the current report on Form 8-K, filed with the SEC on March 2, 2015. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, NanoKnife has been cleared by the FDA for use in the surgical ablation of soft tissue. NanoKnife has not been cleared for the treatment or therapy of a specific disease or condition. This document may discuss the use of NanoKnife for specific clinical indications for which it is not cleared in the United States at this time.

EmboMedics microsphere products have not been reviewed by the U.S. Food and Drug Administration or any other international regulatory body at this time; as such they are currently not available for sale by AngioDynamics.

## Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported non-GAAP sales growth, non-GAAP gross margin, non-GAAP operating income, adjusted EBITDA (income before interest, taxes, depreciation and amortization), non-GAAP net income and non-GAAP earnings per share. Additionally, this press release evaluates results on a constant currency basis. As a non-GAAP measure, constant currency excludes the impact of foreign currency exchange rate fluctuations. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

# Performance Update

## Q4 FY15 Results

	Q4 FY15 Reported	Q4 FY15 <sup>b</sup>
Sales	\$90.9M	\$92.2M
Adjusted EPS <sup>(a)</sup>	\$0.14	\$0.15

## Recent Events

- Next generation AngioVac launched
- 510(k) clearance of a BioFlo Midline catheters
- Dr. Robert Martin, Director of Surgical Oncology, published NanoKnife abstract in the Annals of Surgery
- 510(k) clearance of NanoKnife System generator and FDA issued Certificates to Foreign Governments (CFGs)
- BioFlo DuraMax chronic hemodialysis catheter CE Mark
- First patient treated in CROES NanoKnife prostate cancer trial
- UCLA has initiated RAPID, a multicenter, prospective registry of real world AngioVac use.
- Awarded two contracts by Novation in the quarter, for BioFlo PICCs & Ports
- EmboMedics Agreement
- Celerity “no chest x-ray” claim received

- a) Adjusted results exclude costs relating to acquisitions, debt financing, business restructuring, litigation, facility consolidations, amortization of basis step-up of acquired inventory, revaluation of contingent earn outs related to acquisitions, recalls, product discontinuations and amortization of intangible assets.
- b) On a constant currency basis.



# Profile of AngioDynamics

Global, leading provider of innovative, image guided, minimally invasive solutions.

- Three Franchises – Peripheral Vascular, Vascular Access and Oncology/Surgery
- Founded 1988 | IPO May 2004—ANGO (NASDAQ)
- Worldwide presence with 1,300 employees and 7 operating locations, as well as a 210+ global sales team in U.S., Australia, Canada, France, Germany, Netherlands and UK



- Present in 50+ markets through 110+ distributors



### Innovative Technology

Develop innovative technology that improves patient outcomes while reducing overall healthcare costs



### Above Market Growth

Focusing investments in categories and geographic markets that offer sustainable, profitable growth



### Operational Excellence

Enhancing profitability by driving operation excellence across the entire organization





# Leadership



**Mark Frost**  
EVP & CFO



**Joseph M. DeVivo**  
President & CEO



**John Soto**  
EVP & CCO



**Mark Stephens**  
SVP, Administration



**Stephen Trowbridge**  
SVP & General Counsel



**Benjamin Davis**  
SVP, Business Development



**Barbara Kucharczyk**  
SVP, Operations




**Gary Barrett**  
SVP, RA/QA



# AngioDynamics in FY14

FY14  
4% Sales Growth; 51% GM

Sales by Franchise  
 •Peripheral Vascular: \$193M  
 •Vascular Access: \$106M  
 •Oncology/Surgery: \$49M  
**Total: \$348M\***



\*Excludes BSC supply agreement. With supply agreement FY14 net sales were \$354.5M.



# Growth Driver Performance

Our strategy is working



**23%**

*FY15 over FY14*

AngioVac GROWTH



**65%**

*FY15 over FY14*

BioFlo GROWTH



**25%**

*FY15 over FY14*

NanoKnife GROWTH




**21%**


*FY15 over FY14*

Microwave Ablation GROWTH

# Operational Improvements Plan and Impact

Phase 1 - COMPLETE	Phase 2 – EXECUTING	Phase 3 - PLANNING
<ul style="list-style-type: none"> <li>Implement near term product family consolidation / elimination opportunities </li> <li>Target Indirect procurement supplier consolidation and processes </li> <li>Compress Queensbury shift structure through deployment of Operational Excellence and Capex </li> <li>Re-align manufacturing organizational leadership </li> </ul>	<ul style="list-style-type: none"> <li>Site consolidation:               <ul style="list-style-type: none"> <li>Queensbury repurposed as Distribution Center for NY region </li> <li>Products moved from Queensbury to Glens Falls </li> <li>Manchester as center of excellence for Hardware, Disposables and Ports </li> </ul> </li> <li>Comprehensive product family consolidation </li> <li>Direct procurement consolidation </li> </ul>	<ul style="list-style-type: none"> <li>Global distribution strategy </li> <li>Assess Global manufacturing global footprint: </li> <li>Selective off shoring – e.g. Costa Rica, Malaysia, Singapore </li> </ul>

## OpEx Net Savings Per Year



# AngioDynamics in FY20


FY20

9% 5YR Sales CAGR; 59% GM


Sales by Franchise

- Peripheral Vascular: ~\$300M
- Vascular Access: ~\$200M
- Oncology/Surgery: ~\$100M

Total: ~\$553M



# Strong Product Development Pipeline\*



\*Timelines are estimated and subject to change.



# Clinical Studies\*

PV

SeCure IDE for Expanded EVLT Indication FY18

Next Generation Microwave Ablation Pre-Clinical FY15

O/S

Pancreas NanoKnife Pre-Clinical FY16

CROES II NanoKnife Prostate Study FY17

Prostate NanoKnife IDE FY18

## Investigator Initiated Trials

O/S

- LEIDEN – NanoKnife Pancreas
- CROES Registry
- NEAT – NanoKnife Prostate
- CROES II – NanoKnife Prostate
- AHPBA Registry

PV

- EVLT Registry
- AngioVac Registry

VA

- BioFlo Dialysis
- BioFlo PICCs
- BioFlo Ports

\*Timelines are estimated and subject to change.

# Peripheral Vascular Franchise



<i>\$ in millions</i>	FY15	YoY Growth	FY14 Growth
Fluid Mgmt.	\$80	1%	-4%
Venous	\$52	-4%	18%
Thrombus Mgmt.	\$15	5%	109%
Other Core Products	\$45	0%	7%
<b>Total PV</b>	<b>\$193</b>	<b>0%</b>	<b>7%</b>






# Thrombus Management Market Summary

## Venous Thromboembolism (VTE) Incidence

- Overall ~1 Million VTE Events per Year in U.S.
- Overall 300,000 VTE Deaths per Year in U.S. – #3 cause



## Additional: Annual Incidence

- Catheter/Lead RA: 200,000
- RA Mass: 47,000
- IVCF Thrombosis: 14,000
- TV Endocarditis: 2,500

### Current Treatment Options

- Surgical Embolectomy
- Mechanical / PharmacoMechanical
- Oral Anticoagulation
- Systemic and Catheter Directed Thrombolysis



Source: Heit JA, et al. Blood. 2005;106:267A. Murphy SL, et al. Deaths: Preliminary Data for 2010. National Vital Statistics Reports; 2012





# Vascular Access Franchise



<i>\$ in millions</i>	FY15	YoY Growth	FY14 Growth
PICCs	\$48	-6%	0%
Ports	\$35	7%	3%
Dialysis	\$20	8%	-2%
Total VA	\$108	1%	0%




# BioFlo Technology


The BioFlo family of products, including PICCs, ports and dialysis catheters, are the only vascular access products manufactured with Endexo Technology, a permanent and non-eluting integral polymer.



BioFlo DuraMax at 10X magnification  
Catheter has minimal visible thrombus, fibrin sheath, or clot.



Conventional Non-Coated Catheter at 10x Magnification  
Catheter with thrombus accumulation



Heparin Coated Catheter at 10x Magnification  
Catheter with thrombus accumulation

## Less Thrombus Accumulation

	BioFlo PICCs	BioFlo Ports	BioFlo Dialysis
<i>Vs. common PICC</i>	87% <sup>1</sup>	–	–
<i>Vs. non-coated conventional port catheters</i>	–	96% <sup>2</sup>	–
<i>Vs. non-coated conventional dialysis catheters</i>	–	–	90% <sup>3</sup>
<i>Vs. heparin-coated dialysis catheters</i>	–	–	83% <sup>4</sup>

1. Based on benchtop test results which may not be indicative of clinical results. Data on file. 2. Based on benchtop testing performed up to two hours using bovine blood, which may not be indicative of clinical results. Data on file. 3. The reduction in thrombus accumulation (based on platelet count) is supported by acute in-vitro testing. Pre-clinical in-vitro evaluations do not necessarily predict clinical performance with respect to thrombus formation. 4. Based on benchtop testing performed up to two hours using bovine blood which may not be indicative of clinical results. Data on file.

# Reducing Healthcare Costs

## Clinical Results\*

### Facility 1

- 1,251 BioFlo PICCs placed
- 85% reduction in symptomatic UEDVT
- 7 UEDVTs reported from 1251 PICCs
- UEDVT rate of .45% versus prior 3.1%

### Facility 2

- 272 BioFlo PICCs placed
- 42% reduction in Occlusions
- 19.7% reduction in baseline occlusion rate

### Facility 3


- 776 BioFlo PICCs placed
- 65% reduction in tPA use
- 47% reduction in occlusions

### Facility 4

- 1,212 BioFlo PICCs placed
- 65% reduction in declots
- 36% reduction in DVTs

### Facility 5

- 533 BioFlo PICCs placed
- 66% reduction on occlusions
- 75% reduction in tPA
- 25% reduction in DVTs



\*Clinical results were publicly reported by independent facilities based upon their individual clinical experience. These results do not reflect data gathered by AngioDynamics pursuant to a clinical trial. Individual results may vary from those set forth above.

# Celerity Tip Location

Tip location, coupled with our innovative BioFlo Technology, will improve our competitive position in the PICC market.

## Ease of use

- Use with existing ultrasound

## Clinical efficacy

- Three lead EKG-based platform
- Predictable and reliable confirmation

## Cost effective

- 50% less cost vs. competitors




- Fall 2013 – Canadian Launch
- March 6, 2014 – Acquired regulatory control over Celerity platform and rights to next generation technology
- Mid-summer 2014 – U.S. Clearance
- Fall 2014 – File for no x-ray
- Winter 2014/15 – No x-ray clearance
- Winter Q3 - Navigation

# Leveraging BioFlo to Win Contracted Business

## The Market

5,686  
Registered Acute Care  
Hospitals

5,441  
Acute Care Hospitals  
Purchasing PICCs



4,872  
Hospitals  
Purchasing PICCs  
under a GPO  
Agreement

## AngioDynamics

~30%  
of ANGO Sales  
are Contracted



## GPO Contract History

# of Hospitals that ANGO could officially sell PICCs through a GPO Contract

0

3,688

2012

2013

2014

2015

FDA  
Approves BioFlo  
PICCs  
8/1/2012



Premier  
Awards ANGO PICC  
Contract  
7/1/2013



Novation  
Awards ANGO New  
Technology Award  
for BioFlo PICCs  
8/1/2014



HealthTrust  
Awards ANGO PICC  
Contract 1/1/2015  
8/1/2014






# Oncology/Surgery Franchise

\$225M  
Market

22% Share

<i>\$ in millions</i>	FY15	YoY Growth	FY14 Growth
Thermal Ablation	\$29	-3%	10%
NanoKnife	\$17	25%	7%
Resection/Other	\$6	4%	-18%
Total O/S	\$52	6%	5%






# Expanding Leadership in Tissue Ablation

AngioDynamics offers a full complement of tissue ablation products that provide clinicians maximum choice in treating patients.


THERMAL

NON-THERMAL



# Re-Entering the Embolization Market

On April 9, 2015, AngioDynamics entered an agreement with EmboMedics Inc., which develops injectable & resorbable microspheres and expects to file for U.S. FDA 510(k) clearance for the embolization of hypervascular tumors by January 2016.



## \$150M

Worldwide  
Addressable Market

### Terms

- Initial \$2M equity investment
- May make \$9M additional investments based on milestones


### Investment Strategy

- ✓ Novel Technology
- ✓ Highly margin accretive
- ✓ Worldwide rights for direct and distributor sales
- ✓ Pathway to own technology



# International Growth Strategy

## International Quarterly Growth Rates



## Market Led, Efficient & Aligned

- Region-based business model improves competitiveness
- Increased direct market expansion
- New product introductions and full registration of product portfolio
- Delivering operating margin improvement
- Align talent and organization to ensure consistent execution of Company's strategy



a) On a constant currency basis.

# Fiscal Fourth Quarter and Full Year Results

## Sales

\$ in millions, except per share amounts

	Q4 2015 <sup>(a)</sup>	YOY Growth	FY15 Growth
WW	\$90.9	-3%	1%
WW <sup>(c)(d)</sup>	\$91.2	-2%	2%
PV	\$49.8	-2%	0%
VA	\$27.1	-4%	1%
O/S	\$13.0	-5%	6%
U.S. <sup>(c)</sup>	\$72.0	-2%	0%
Int'l	\$17.9	-6%	5%
Int'l <sup>(d)</sup>	\$19.2	0%	9%
	Q4 2015 <sup>(b)</sup>	YOY Growth	FY15 Growth
Adjusted EBITDA	\$13.4	-14%	4%
Adjusted EPS	\$0.14	-22%	3%
Adjusted EPS <sup>(d)</sup>	\$0.15	-17%	10%

## Fiscal Guidance\*

\$ in millions, except per share amounts

	Q1	Full-Year
Sales <sup>(d)</sup>	\$83-\$87	\$364-\$370
Adjusted EPS <sup>(b)</sup>	\$0.10-\$0.12	\$0.62-\$0.66

\*Guidance is as of July 2015. No updates have been provided since this date.

- (a) There is no difference in the number of sales days between the fiscal 2015 and fiscal 2014 periods.  
 (b) Adjusted results exclude costs relating to acquisitions, debt financing, business restructuring, litigation, facility consolidations, amortization of basis step-up of acquired inventory, revaluation of contingent earn outs related to acquisitions, recalls, product discontinuations and amortization of intangible assets.  
 (c) Excludes impact of our supply agreement.  
 (d) Constant-currency basis.



# AngioDynamics Transformation

## Investor Profile

- Major acquisitions – Navilyst (2012), Vortex Medical (2012), Microsulis (2013)
- Disruptive technology in PV, VA & O/S markets with strong product pipeline
- Significant International opportunity
- Operational Excellence Program in place to drive margin expansion
- Emerging GPO presence



	FY11	FY12	FY13	FY14	FY15
<i>Net Sales</i>	\$216M	\$222M	\$342M	\$354M	\$357M
<i>Reported Growth</i>	0%	3%	54%	4%	1%
<i>Pro Forma</i>	0%	3%	-1% <sup>a</sup>	4%	1%
<i>Exc. BSC/FX</i>	-	-	-	5%	2%



a) On a pro forma basis prior year sales for AngioDynamics and Navilyst Medical were \$344.6 million.

**UBS 2015**

# **SMID Cap One-on-One Conference**

**Mark Frost, Executive Vice President & CFO**

August 5, 2015



# Balance Sheet & Cash Flow

<i>\$ in millions</i>	May 31, 2015	May 31, 2014
Cash & investments	\$20.1	\$17.9
Net working capital	\$94.7	\$85.0
Total	\$773.6	\$798.9
assets		
Total debt	\$137.7	\$142.7
Total stockholder's equity	\$545.0	\$536.8

<i>\$ in millions, except per share amounts</i>	Year ended May 31, 2015	Year ended May 31, 2014
Cash flow from operations	\$26.2	\$24.7
CFFO/share	\$0.72	\$0.70
Free cash flow	\$14.3	\$13.5



# Adjusted Income Statement<sup>(a)</sup>

<i>\$ in millions, except per share amounts</i>	Year ended May 31, 2015	Year ended May 31, 2014
Sales	\$357.0	\$354.4
Gross margins	50.9%	50.7%
Operating expenses	\$141.6	\$141.2
Operating income	\$40.1	\$38.7
Operating margin	11.2%	10.9%
Net income	\$21.2	\$20.0
EPS	\$0.58	\$0.56
EBITDA	\$57.2	\$55.0

a) Adjusted results exclude costs relating to acquisitions, debt financing, business restructuring, litigation, facility consolidations, amortization of basis step-up of acquired inventory, revaluation of contingent earn outs related to acquisitions, recalls, product discontinuations and amortization of intangible assets.

